Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Zapisane w:

Opis bibliograficzny
1. autor:	Ti Wen (15130158) (author)
Kolejni autorzy:	Whitney Barham (3519266) (author), Ying Li (38224) (author), Henan Zhang (15039950) (author), Joanina K. Gicobi (15112708) (author), Jacob B. Hirdler (15130161) (author), Xin Liu (43569) (author), Hyoungjun Ham (1379232) (author), Kodi E. Peterson Martinez (15130164) (author), Fabrice Lucien (190431) (author), Roxane R. Lavoie (12782390) (author), Hu Li (130600) (author), Cristina Correia (14937743) (author), Dileep D. Monie (15130167) (author), Zesheng An (1488511) (author), Susan M. Harrington (14995181) (author), Xiaosheng Wu (358753) (author), Ruifeng Guo (3932663) (author), Roxana S. Dronca (8604987) (author), Aaron S. Mansfield (15033804) (author), Yiyi Yan (15128922) (author), Svetomir N. Markovic (10662246) (author), Sean S. Park (15039986) (author), Jie Sun (74648) (author), Hong Qin (279614) (author), Minetta C. Liu (15032247) (author), George Vasmatzis (69257) (author), Daniel D. Billadeau (15014748) (author), Haidong Dong (15039983) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Biological Agents & Therapies Gene therapy Immunology Immune responses to cancer Immunomodulation Immunotherapy Checkpoint blockade Single Cell Technologies
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Figures from NKG7 Is Required for Optimal Antitumor T-cell Immunity
od: Xian-Yang Li (15022958)
Wydane: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
od: Aleksandar Obradovic (7549517)
Wydane: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
od: Aleksandar Obradovic (7549517)
Wydane: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
od: Zhihang Chen (17315678)
Wydane: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
od: Kankan Cao (16437263)
Wydane: (2025)

Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer
od: Sunho Park (15053897)
Wydane: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Wydane: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Wydane: (2025)

Processed single-cell RNA-seq dataset of cancer-associated fibroblasts in breast cancer patients receiving anti–PD-1 therapy
od: Thang Pham (19938126)
Wydane: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
od: Snehanshu Chowdhury (14957031)
Wydane: (2025)

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
od: Dong-Chun Hong (16374308)
Wydane: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
od: Xiaodong Shu (16721586)
Wydane: (2025)

Suppl. Figure 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Suppl. Figure 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Suppl. Figure 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Suppl. Figure 4 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Suppl. Figure 5 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Suppl. Figure 6 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Supplementary Data 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Supplementary Data 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Supplementary Data 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
od: Teresa González-Muñoz (16797866)
Wydane: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
od: Alessio Cortellini (11023993)
Wydane: (2025)

Data Sheet 1_Complementary therapies intervention in Parkinson’s disease: systematic review and meta-analysis.docx
od: Fabio Sabbadin (22686242)
Wydane: (2025)

Supplementary video 1 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
od: Alvaro Teijeira (14962650)
Wydane: (2025)

Supplementary video 2 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
od: Alvaro Teijeira (14962650)
Wydane: (2025)

Supplementary video 3 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
od: Alvaro Teijeira (14962650)
Wydane: (2025)

Data Sheet 1_An evolving role in the NICU: a study of the tasks, knowledge, skills, and practice demographics of the neonatal therapist.pdf
od: Alicia Fernandez-Fernandez (9139193)
Wydane: (2025)

Table S1 from Dysregulation of Mitochondrial Translation Caused by <i>CBFB</i> Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
od: Navdeep Malik (15293148)
Wydane: (2025)

Table S2 from Dysregulation of Mitochondrial Translation Caused by <i>CBFB</i> Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
od: Navdeep Malik (15293148)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_2kv38r2ec9aq2tmi65r7b5prod